Format

Send to

Choose Destination
Can J Ophthalmol. 2014 Oct;49(5):431-5. doi: 10.1016/j.jcjo.2014.07.012.

Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD.

Author information

1
Ophthalmic Clinic Jasne Blonia, Rojna 90, Lodz, Poland; Third Municipal Hospital, K. Jonscher, Milionowa 14, Lodz, Poland.
2
Third Municipal Hospital, K. Jonscher, Milionowa 14, Lodz, Poland.
3
Ophthalmic Clinic Jasne Blonia, Rojna 90, Lodz, Poland; Third Municipal Hospital, K. Jonscher, Milionowa 14, Lodz, Poland. Electronic address: zosia_n@yahoo.com.

Abstract

OBJECTIVE:

This study aimed to report on the efficacy of 1 dose of aflibercept in bevacizumab nonresponders.

DESIGN:

This was a retrospective, single-centre, interventional, noncomparative study.

PARTICIPANTS:

This study retrospectively analyzed 23 patients with persistent intraretinal or subretinal fluid treated with 6 or more monthly bevacizumab injections.

METHODS:

Patients were switched to 1 dose of aflibercept and afterward continued their therapy with bevacizumab for at least another 6 months. We performed spectral domain optical coherence tomography monthly and evaluated visual acuity, central retinal thickness, and photoreceptor defects. The main outcome measures were visual and anatomic outcome 1 and 6 months after administering aflibercept.

RESULTS:

Visual acuity significantly improved (p = 0.01) after the switch to aflibercept (from 0.39 to 0.49 Snellen). This improvement was stable for the remaining 6 months of the study (final visual acuity, 0.46 Snellen); 47% of patients experienced an improvement of at least 5 letters from baseline on a chart of the ETDRS type (Early Treatment Diabetic Retinopathy Study). Central retinal thickness decreased from 521 µm to 446 µm (p = 0.01) and remained stable for the next 6 months (452 µm). Complete resolution of intraretinal and subretinal fluid was observed in 30% of eyes.

CONCLUSIONS:

In bevacizumab nonresponders, switching to a single dose of aflibercept before continuing the therapy with bevacizumab improves visual outcome and anatomic results.

PMID:
25284099
DOI:
10.1016/j.jcjo.2014.07.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center